Ligon Discovery to Screen Candidates for Bayer Schering | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Ligon Discovery today said that it will use its Small Molecule Microarray (SMM) screening platform to discover candidates for Bayer Schering Pharma's drug development programs.

The Cambridge, Mass.-based firm said that its technology works by affixing drug candidates to a slide, enabling it to use cell lysates, instead of "developing a complex assay based on a full understanding of a protein target's functions."

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: miR-515 levels higher in women with preeclampsia, horizontal gene transfer in parasitic plants, and more.

A cancer researcher retracts 19 articles from one journal for image manipulation, according to Retraction Watch.

Precision medicine has to consider context in addition to genetic mutations in cancer treatment, Medscape reports.

Genomics may help the Cavendish banana from succumbing to fungal infections, a trio of researchers writes at the Conversation.